Catastrophic antiphospholipid syndrome
Rare autoimmune disease causing widespread clotting and multi-organ failure.
Catastrophic antiphospholipid syndrome (CAPS), also called Asherson's syndrome, is a rare autoimmune condition where widespread clotting inside blood vessels leads to multiple organs failing. It stems from antiphospholipid antibodies that attack proteins in the body linked to phospholipids. These antibodies activate endothelial cells, platelets, and immune cells, triggering a massive inflammatory immune response and extensive clotting. Ronald Asherson first described the syndrome in 1992. CAPS involves thrombotic microangiopathy, clots in many organs, and sometimes tissue death, marking it as a severe, catastrophic form of antiphospholipid syndrome. Clinically, CAPS affects at least three organs and can involve many systems. It often features small-vessel clots in areas like the gastrointestinal tract and signs of acute respiratory distress syndrome (ARDS), a type of systemic inflammatory response syndrome (SIRS). Peripheral clots may occur in veins and arteries. Clots inside the abdomen can cause pain. The body has β2-GPI, a blood glycoprotein that acts as a natural anticoagulant by inhibiting certain platelet functions. Since anti-β2-GPI antibodies can form after bacterial exposure, the body becomes prone to excessive clotting, which activates toll-like receptor 4 and leads to a cytokine storm or thrombotic storm. A thrombotic storm can also arise from changes in coagulation and fibrinolysis that raise death rates, or from infections in children where IgM and IgG anti-β2-GPI antibodies signal endothelial cells to promote clotting. It is thought that prothrombotic genetic risk factors may speed up clotting after a first event, rather than environmental factors alone causing it. Complications often involve the heart, blood vessels, nerves, kidneys, and lungs. Heart issues include mitral valve regurgitation (where the valve leaks blood backward), angina (chest pain), and myocardial infarction (heart attack). Kidney problems can lead to low urine output and high blood pressure. Lung issues may cause rapid breathing (hyperventilation) and low oxygen levels (hypoxemia). The skin may show purpura and necrosis. Brain involvement can cause encephalopathy and seizures. Heart attacks and strokes from arterial clots may occur. Death can result from multiple organ failure.
- Field
- Autoimmune disease
- Known for
- Rare, catastrophic variant of antiphospholipid syndrome causing multi-organ failure
- First described by
- Ronald Asherson
- Year first described
- 1992
- Alternative name
- Asherson's syndrome
Lore & Background
Catastrophic antiphospholipid syndrome is caused by antiphospholipid antibodies that target proteins associated with phospholipids, activating endothelial cells, platelets, and immune cells. This triggers a large inflammatory immune response and widespread clotting. The syndrome usually affects at least three organs, often involving small vessel thromboses in the gastrointestinal tract and manifestations of acute respiratory distress syndrome. Peripheral thrombosis may affect veins and arteries, and intra-abdominal thrombosis can cause pain.
Reader's Guide
The syndrome's significance lies in its high morbidity and mortality, requiring aggressive multidisciplinary treatment. Diagnosis requires three or more new organ thromboses within a week, confirmed by biopsy showing microthrombosis. Treatment includes anticoagulation, glucocorticoids, plasma exchange, and intravenous immunoglobulins. The syndrome can lead to complications such as mitral valve regurgitation, myocardial infarction, kidney failure, and strokes. In pregnant women, 54% experienced fetal loss and about 50% died from complications. The condition underscores the interplay between autoimmune antibodies and thrombotic storms.
Did You Know?
- CAPS was first described by Ronald Asherson in 1992.
- The syndrome requires three or more new organ thromboses within a week for a definite diagnosis.
- 54% of pregnant mothers with CAPS experienced fetal loss.
- Treatment may include intravenous heparin, corticosteroids, and plasma exchanges.
More in Syndromes 1-24
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced
